neurometabolic disorders - sweetser · neurometabolic disorders david sweetser, md, phd chief of...
TRANSCRIPT
![Page 1: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/1.jpg)
Neurometabolic Disorders
DavidSweetser,MD,PhDChiefofMedicalGeneticsandMetabolism
MassGeneralHospitalfor Children
Sept. 5, 2017
![Page 2: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/2.jpg)
Disclosures
• None
Acknowledgement – Neela Sahai, MD
![Page 3: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/3.jpg)
LearningObjectives
• Cluesyouaredealingwithametabolicdisorder
• Hallmarksofthemajorclassesofmetabolicdisorders
• Diagnosticandtreatmentstrategies
![Page 4: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/4.jpg)
Importance
• Rare,butinaggregatesignificantburdenofpediatricmorbidity
• Timelyinstitutionofspecifictreatmentsmaypreventpermanentneurologicalimpairment
• Familialimplications
![Page 5: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/5.jpg)
InbornErrorsofMetabolism
ØSinglegenedefectsØDefectsinanenzymeortransportproteinØAbnormalitiesinthesynthesisorcatabolismofproteins,carbohydrates,fats,orcomplexmolecules.
ØIndividuallyrarebutcollectivelynumerous
![Page 6: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/6.jpg)
NeurologicalManifestations
ØDevelopmentaldelayØVisual/auditorylossØAtaxia,Encephalopathies,myelopathies,neuropathies,seizures,braindysgenesis…..
ØAdultonset– psychiatric,aggression,mood/behavioraldisorders
ØNeuroimagingoftenhelpful
Common in IEM, may be only manifestation
![Page 7: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/7.jpg)
ImagingFindingsinIEM
* - macrocephaly, ** enhancementAmerican Journal of Roentgenology. 2014;203: W315-W327
![Page 8: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/8.jpg)
ChallengesinDiagnosis
• Commonnon-specificsymptoms– Poorfeeding– hypotonia– Sepsis– Vomitinganddehydration– Developmentaldelay,behavioralproblems– Seizures
• ClinicalHeterogeneity– Symptoms,onset,progression
![Page 9: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/9.jpg)
CluestoDiagnosis
• Prioraffected/abnormal/lostchild• Parentalconsanguinity• Developmentalregressionorplateau• Body/urineodor,micro/macrocephaly,Sz• Dysmorphology,“coarsefeatures”• Hepatomegaly,skeletalanomalies• Episodicdecompensations
![Page 10: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/10.jpg)
ClinicalPresentations
ØAcutesymptomsinneonatalperiodØIntermittent/RecurrentsymptomsØLater-onsetacutesymptomsØChronicandprogressivenonspecificsymptoms
ØSpecificandpermanentsymptoms
![Page 11: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/11.jpg)
NeonatalPresentation
• Fulltermnormalnewbornthatdeteriorateswithoutapparentclinicalcause– Seizures– Feedingdifficulties– Hypotonia– Lethargy– Vomiting/dehydration– Respiratorydistress
![Page 12: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/12.jpg)
JuvenileOnset
• Episodicdecompensations– Withcatabolism,intakespecificfood(protein)– Withfever,exercise
• Symptoms– Poorfeeding,vomiting,lethargy,Sz,MS∆– Metabolic– acidosis,hypoglycemia,hyperammonemia
– Ataxia– Death
![Page 13: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/13.jpg)
Chronicprogressive
• Lossofmotor,cognitive,speechabilities• Systemicfindings
– Skeletal,HSM,ophthalmologic(retina,lens)• Coarsefeatures• Newonsetseizures,spasticity,hyperreflexia,ataxis
![Page 14: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/14.jpg)
ClinicalAssociations• Psychosis/catatonia– Ureacycledisorders,Neimann PickTypeC,
acuteintermittentporphyria,hereditarycoporphyria,homocystinuria,TaySachs,Wilsons
• Peripheralneuropathy– Fabrydisease,porphyria,Vit (B12,E,B1)def,POLG1,mitochondrialDOs
• Neutropenia – organicacidurias,GSDIb
• Macrocephaly– Glutaric aciduriaTypeI(+ICH),D-2-hydroxyglutaricaciduria,Canavandisease,Alexander,Megalencephalic leukodystrophy
• Progressiveexternalophthalmoplegia- ANT1,Twinkle, POLG1,myotonicdystrophy,SCA,MNGIE
![Page 15: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/15.jpg)
METABOLIC PATHWAYS
![Page 16: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/16.jpg)
Pathophysiology
ØToxicaccumulationofmetabolites
ØImpairedenergyproduction/utilization
ØDecreasedsynthesisorcatabolismofcomplexmolecules
![Page 17: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/17.jpg)
ToxicMetabolites
• Aminoacid(MSUD,PKU)• Organicacidurias(MMA,PA,IVA)• Carbohydrate(galactosemia,fructoseintolerance)
• Cholesterol(SmithLemli Opitz,NiemannPickTypeC)
• Copper(Menkes,Wilsons)• Neurotransmitters(tetrahydrobiopterindef)
![Page 18: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/18.jpg)
ToxicMetabolites- Features
• Usuallynotdysmorphic• Intervalswithoutsymptoms• Acute,episodic,orchronicdecompensation• Triggers– ingestions,illness,fasting
• DX– labtesting• Rx– preventcatabolism,diet,clearance
![Page 19: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/19.jpg)
NewbornScreening- PKU
![Page 20: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/20.jpg)
PKU
• SevereID• Postnatalmicrocephaly• BehavioralDO,ASDs• Seizures• Rashes• Decreasedpigmentation• Odor– “mousy”,“musty”
(phenyllactate,phenylpyruvate)
phenylalanine
tyrosine
Phenylalaninehydroxylase
BH4
High signal intensity in white matter regions around anterior and posterior horns of both lateral ventriclesand brain atrophy in phenylketonuria
Iran J Child Neurol. 2015 Winter; 9(1): 1–16.
![Page 21: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/21.jpg)
PKU
http://www.ncbi.nlm.nih.gov/books/NBK55827/
Specific Therapy Guidelines
Confirmation testing
![Page 22: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/22.jpg)
Glucose Fatty Acids
Urea
Urea Cycle
Ammonia TCA Cycle
PyruvateAcetyl CoA
RespiratoryChain
ATP
Amino Acids
Organic Acids
![Page 23: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/23.jpg)
OrganicAcidDisorders
ØMetabolicabnormalitiesØ Systemicinvolvement(includingneurological)
“CLASSICAL/TYPICAL”
“CEREBRAL”
ØMetabolicderangementabsentØ Exclusivelyneurological
•Propionic Acidemia•Methylmalonic Acidemia (+Cbl A,B,C def)
•Isovaleric Acidemia•Multiple Carboxylase Deficiency•Multiple Co-A Dehydrogenase Deficiency (Glutaric Acidemia,Type 2)•Maple Syrup Urine Disease
•Glutaric Acidemia-I
•N-acetylaspartic Deficiency
•Succinic Semialdehyde Dehydrogenase Deficiency
•L-2 hydroxyglutaric Aciduria
![Page 24: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/24.jpg)
CatabolismofBranchedChainAminoAcidsLeucine Isoleucine Valine
2-oxoisovaleric acid2-oxocaproic acid 2-oxo-3-methyl-valeric acid
2-methylbutyryl-CoA Isobutryl-CoAIsovaleryl-CoA
3 methylcrotonyl-CoA2-methyl-acetoacetyl-CoA
3-hydroxy 3-methyl-glutaryl-CoA
3-hydroxy isobutyric acid
Acetoacetate Acetyl-CoA
3-methylmalonic semialdehyde
Propionyl-CoA
Methylmalonyl-CoA Succinyl-CoA
MSUD
IVA
PAMMA
![Page 25: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/25.jpg)
AcutePresentation
ØPoorfeedingØVomitingØLethargy/ChangeinneurologicalstatusØRespiratorydistressØAbnormalmuscletoneØSeizures
AgeofOnset&SeverityVariable
![Page 26: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/26.jpg)
GeneralLaboratoryFindings
ØMetabolicacidosiswithincreasedaniongapØKetosisØHyperammonemiaØHypoglycemiaØNeutropeniaØThrombocytopeniaØElevatedamylase/lipase
![Page 27: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/27.jpg)
ØUrineorganicacidanalysisbyGC/MSØPlasmaaminoacidanalysis
• Elevatedglycine• BranchedchainaminoacidsincreasedinMSUD• Otherwise,typicallynormal
ØPlasmaacylcarnitineprofileØUrinaryacylglycine profile
DiagnosticTesting
![Page 28: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/28.jpg)
Non-AcutePresentationØDevelopmentaldelays+/- SeizuresØFailuretothriveØChronicvomitingØHypotoniaØRecurrentinfectionsØRecurrentpancreatitisØCardiomyopathy (especiallyPA)ØRenalDiseaseØOdors(SweatyFeetinIVA,MADD;BurntSugarinMSUD)
![Page 29: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/29.jpg)
NeurologicalComplications
ØMetabolic“stroke”(acuteorprogressiveextrapyramidal symptoms):MMA,PA,IVA
ØOpticatrophyandretinitis:MMA,PAEvidencesuggestsopticatrophyandstroke(andcardiomyopathy)duetosecondarydefectsinrespiratorychain.
![Page 30: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/30.jpg)
Delayed Brain Maturation
Myelination delay, Immature gyral pattern, Incomplete opercularization, Hypoplastic corpus callosum cerebellar vermis
Basal Ganglia Lesions
PallidumPutamenCaudate
Irreversible volume loss (predominantly supratentorial atrophy).
Progressive White MatterChanges
Neuroimaging
Brainstem and Cerebellar Changes
![Page 31: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/31.jpg)
Imaging:AcutePresentation
MRI of MMA patient aged 20 daysBilateral lesions of the pallidum with swelling and restricted diffusion as the most prominent finding
J Inherit Metab Dis (2008) 31:368–378
![Page 32: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/32.jpg)
MRI at age 12 months: D. Severely delayed myelinationE. The pallidum appears slightly T2 hyperintense, but this is not definitely abnormal at a maturation stage of 6 months F. Sagittal images demonstrate a thinned corpus callosum dorsally and a wide foramen of Magendi , the latter apparently due to slight volume reduction of the inferior vermis.
Neuro-Imaging
I Harting et al. Looking beyond the basal ganglia: The spectrum of MRI changes in methylmalonic acidaemia. J Inherit Metab Dis (2008) 31:368–378
![Page 33: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/33.jpg)
Imaging:PropionicAcidemia
Abnormal Signal in Bilateral Basal Ganglia and Brain Atrophy in an MRI from a 4-year-old boy with propionic-acidemia
Iran J Child Neurol. 2015 Winter; 9(1): 1–16.
![Page 34: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/34.jpg)
ØPresymptomatic treatment• DietaryTreatment:Reduceintakeofoffendingaminoacids
viarestrictionofnaturalproteinwhilemaintainingasufficientintakeofessentialnutrientsandenergysubstrates)
• Aminoacidsupplements• Carnitine• CofactorsØEarlyaggressivetreatmentofintercurrentillness
ØManagementofmetaboliccrisisØTreatmentofmanifestations
Treatment
![Page 35: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/35.jpg)
“Cerebral”OrganicAcidDisorders
ØMetabolicabnormalitiesgenerallyabsentØ Elevationofdiagnosticmetabolites(organicacids)maybeslight.
Ø Progressiveneurologicalsymptoms•Epilepsy•Macrocephaly •Metabolicstroke•Extrapyramidal symptoms•Ataxia•Myoclonus
Ø Progressivefindingsonneuro-imaging•Disturbancesofmyelination•Cerebellar atrophy•Frontotemporal atrophy•Hypodensities/infarctsofbasalganglia•Symmetricalpathologyapparentlyindependentofvascularsupply.
![Page 36: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/36.jpg)
Glutaric Aciduria-TypeIØMacrocephaly atbirth(~50%)Ø Softneurologicalfindings:HypotoniaØAcuteencephalopathic crisisat3–18months
• Often butnotalwaysprecipitatedbyintercurrent illness• Rapid(24-48hrs)lossofneuronsincaudateandputamen• Subsequentdystonia,choreoathetosis,significantmotordisabilities
• Cognitiveabilitiesareoftenpreservedtilllateincourse
Ø Episodesmayberecurrent,butdisabilitymostoftenduetoasingleepisodeofacutestriatal necrosis
Ø ClinicalSpectrum:Developmentaldelaysfrombirthtoasymptomaticcase
![Page 37: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/37.jpg)
A,B.FrontotemporalatrophyC.HighsignalintensitiesincaudateandputamenD.EdemawithacuteepisodeE.Eventualatrophycaudate,putamenF.Subduralhygromas,hemorrhages
Am J Med Genet C Semin Med Genet. 2006 May 15; 142C(2): 86–94.
MRIFindings:GA-I
![Page 38: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/38.jpg)
GlutaricAciduria-TypeI
Acetyl CoA
Lysine Tyrptophan
Crotonyl CoA
Glutaryl CoA
FAD
FAD- 2H
ØDiagnosis:• UOA- Glutaric&3-hydroxyglutaricacids• Plasmaacylcarnitines- Glutarylcarnitine (C5DC)*• EnzymeandGCDHgeneanalysis
Ø Pathogenesis:• StriataltoxicityofGA• Metabolitesactasglutamateanalogsatthe
NMDAreceptorsandGlutamatereceptors• InhibitionofGABAsynthesis• Mitochondrialtoxicity
Glutaryl CoAdehydrogenase
*Note – low excretors missed on NBS
![Page 39: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/39.jpg)
ØPresymptomatic treatmenttopreventencephalopathic crisis&neurologicalsymptoms
• DietaryTreatment:ReduceLysineintakeviarestrictionofnaturalproteinwhilemaintainingasufficientintakeofessentialnutrientsandenergysubstrates)
• Lysinefreeaminoacidsupplements• Carnitine• Riboflavin:InriboflavinresponsivecasesØEarlyaggressivetreatmentofintercurrentillness(especiallybeforeage6years)
GA- ITreatment
![Page 40: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/40.jpg)
Ø Baclofen &diazepamasfirstlinetreatmentfordystonia.
Ø Intrathecal baclofen forseveredystonia/spasticity.Ø Trihexyphenidyl assecond-linetreatmentfordystonia.
Ø Botulinum toxinasadditionaltherapyforseverefocaldystonia.
Ø AvoidAntiepileptics,L-dopaandamantadine forthetherapyofmovementdisordersinGA-I.
Ø Long-termbenefitofdystonic patientsfrompallidotomy isuncertain
ØAvoidValproate
GA- I:TreatmentofNeurologicalComplications
![Page 41: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/41.jpg)
CanavanDisease
ØMacrocephaly,Hypotonia,DevelopmentalDelays:Apparentby3-monthsofage.
Ø Severemotordelays.ØWithagehypotoniagiveswaytospasticity.ØOpticatrophymaybepresent.NohearinglossØ Seizures,SleepdisturbancesØ Variablelifeexpectancy;usuallyintoteens.Ø ClinicalSpectrum:Mildformexists
![Page 42: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/42.jpg)
CanavanDisease:MRS
markedly increased level of N-acetylaspartic acid (NAA)
Iran J Child Neurol. 2015 Winter; 9(1): 1–16.
![Page 43: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/43.jpg)
ØDiagnosis:• Urine-IncreasedN-acetylaspartate• EnzymeandASPAgeneanalysis
Ø Pathogenesis:• Deficiencyofacetateresultinginimpairedoligodendrocyte maturationand
myelination• OxidativestressinducedbyNAA• ExcitationofNMDAreceptorsandGlutamatereceptors• ExcessNAAimpairsosmoticbalance
Canavan Disease
N-acetylaspartate
Acetate Aspartic Acid
Aspartoacylase
![Page 44: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/44.jpg)
Canavan Disease:TreatmentØPrimarilysupportive,trialsexistØ Glyceryltriacetate (4.5g/kg/d)1:• 2infants;Ages8months&1yr;treatedfor4.5&6monthsrespectively.• Nosignificantsideeffects/toxicityobserved• Nomotorimprovement. (earliertreatment??)Ø LithiumCitrate(45mg/kg/day)2:• 6infants;Meanage9.5monthstreatedfor6weeks.• Nosignificantsideeffects/toxicityobserved.• ModestdropinNAA• Alertnessimprovedbutnomotorimprovement(onGMFT).(stabilized?)• Imaging:DTIimages(n=2)acrossCCsuggestedmicro-structural
improvement.ModestdropinT1relaxationtimesonselectedbrainareas(CCandFWM)
Ø LipoicAcid(antioxidant)
1. Segal R et al. A safety trial of high dose glyceryl triacetate for Canavan disease. Mol Genet Metab. 2011 Jul;103(3):203-6.2.Assadi M et al. Lithium citrate reduces excessive intra-cerebral N-acetyl aspartate in Canavan disease.Eur J Paediatr Neurol. 2010 Jul;14(4):354-9.
![Page 45: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/45.jpg)
SuccinicSemialdehyde DehydrogenaseDeficiency
Ø PsychomotorretardationØHypotoniaØ AtaxiaØ Seizures(~50%)ØHyperkinetic,aggressiveandself-injuriousbehaviorØ HallucinationsØ SleepdisturbancesØ Basalgangliasigns(choreoathetosis,dystonia &myoclonus)infew
![Page 46: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/46.jpg)
Glutamate
GABA
Succinic Semialdehyde
Succinate
TCA Cycle
Succinic semialdehyde dehydrogenase
gamma-hydroxybutyrate
Glutamic acid decarboxylase
GABA transaminaseSSAreductase
GHB dehydrogenase
Succinic Semialdehyde DehydrogenaseDeficiency
DiagnosticLaboratoryInvestigations
UrinaryOrganicAcids:Elevated4-hydroxybutyrate*Enzyme(Leucocytes)andALDH5A1 geneanalysis
PathogenesisDownregulationofGABAReceptors
*Volatile – may be missed on UOA (CSF)
![Page 47: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/47.jpg)
MRI Findings Succinic SemialdehydeDehydrogenase Deficiency.
P. L. Pearl et al. Neurology 2003;60:1413-1417
©2003 by Lippincott Williams & Wilkins
T2hyperintensitiesGlobuspallidi (43%)Cerebellardentatenucleus(17%)Subcorticalwhitematter(7%)Brainstem(7%)
Alsocerebralor/andcerebellaratrophy,anddelayedmyelination.
![Page 48: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/48.jpg)
ØManagement of manifestations• Antiepileptics: o Carbamazepine & Lamotrigineo Vigabatrin (irreversible inhibitor of GABA-transaminase)-
Inconsistent results.o Avoid Valproate• Neurobehavioral: Methylphenidate, thioridazine,
risperidal, fluoxetine, and benzodiazepines.
SuccinicSemialdehyde DehydrogenaseDeficiency:Treatment
ØUnder Investigation • Taurine, rapamycin, SGS-742 GABA-B R antagonist
![Page 49: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/49.jpg)
Seizures
•Non ketotic hyperglycinemia •Sulfite Oxidase Deficiency
UREACYCLEDISORDERS
NONKETOTICHYPERGLYCINEMIA
SULFITEOXIDASEDEFICIENCYHOMOCYSTINURIA
PHENYLKETONURIA
AminoAcidDisordersNeonatal Period
•Urea Cycle Defects•Non ketotic hyperglycinemia •Sulfite Oxidase Deficiency
Acute Ataxia
•Urea Cycle Defects (ASA, OTC)
Thromboembolic Events
• Homocystinuria
•Serine Deficiency
Only few examples shown here
![Page 50: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/50.jpg)
UreaCycleDisordersGlutamineAlanineGlycineAspartateGlutamate
Ammonia
Carbamoylphosphate
Nitrogen Pool
Citrulline
Citrulline
Ornithine
Ornithine
Argininosuccinate Arginine
Fumarate
Urea
Nacetylglutamate
Aspartate
Carbamoylphosphate synthetase
N acetylglutamate synthetase
Ornithine transcarboxylase
Argininosuccinic synthetase
Argininosuccinic lyase
Arginase
Mitochondria
Cytosol
NAGS
CPS
OTC
ASS
ASL
![Page 51: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/51.jpg)
UreaCycleDisordersGlutamineAlanineGlycineAspartateGlutamate
Ammonia
Carbamoylphosphate
Nitrogen Pool
Citrulline
Citrulline
Ornithine
Ornithine
Argininosuccinicate Arginine
Fumarate
Urea
Nacetylglutamate
Aspartate
Carbamoylphosphate synthetase
N acetylglutamate synthetase
Ornithine transcarboxylase
Argininosuccinic synthetase
Argininosuccinic lyase
Arginase
Mitochondria
Cytosol
NAGS
CPS
OTC
ASS
ASL
Hippurate
+PhenylbutyratePhenylacetylglutamine
Orotic Acid
![Page 52: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/52.jpg)
AcutePresentation
ØHyperammonemic EncephalopathyØ RareinArginase DeficiencyØHyperventilationisanearlyfindingØ Inmilderformstriggeredbystress/illnessØOutcomesdependonseverityanddurationofhyperammonemia
ØDamageresembleshypoxic-ischemiceventsorstroke.Lacunar infarctsandwhitematterdisruptionarecommonfindings
![Page 53: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/53.jpg)
UreaCycleDefects
ØNAGS:SimilartoCPS
ØCPS:Consideredmostsevere;Noorotic acid.Ø OTC:Xlinked.15%O + hyperammonemia
ØASS(CITI)ØASL(ASA):Trichorrhexis nodosa.Hepaticenlargementandfibrosis.
ØARG:Acutepresentationuncommon.Pogressivespasticitymostcommonpresentation.Alsotremor,ataxia,andchoreoathetosis
![Page 54: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/54.jpg)
Diagnosis
ØAmmoniaØElectroloytes &BloodGasesØPlasmaAminoAcidsØUrinaryOrotic AcidØMolecularTesting
![Page 55: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/55.jpg)
TreatmentØTreatmentofAcuteHyperammonemia• IVNitrogenScavengerDrugs• Hemodialysis• SupplementationwithArginine,Citrulline&Carbamyl
glutamate(dependingondisorder)
ØLongTermManagement:• Dietaryrestrictionofprotein• Useofspecializedformulas• Oralnitrogen-scavengingdrugs.• SupplementationwithArginine,Citrulline&Carbamyl
glutamate• AvoidanceofValproic acid,Prolongedfastingorstarvation,
Intravenoussteroids,Largebolusesofproteinoraminoacids.
![Page 56: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/56.jpg)
§ Progressivelethargy§ Hypotonia§Myoclonic Jerks§ Apnea
SEVERE
MILD
§ Hypotonia§ Delays§ Seizures
NEONATAL
INFANTILE
80%
20%
50%
§Limiteddevelopment(DQ<20).§Intractableseizures§Progressivespasticity§Swallowingdysfunction
§ DQ(20-60).§Seizures§Limitedspasticity§Hyperactive§Choreic movements
Non-Ketotic Hyperglycinemia(GlycineEncephalopathy)
![Page 57: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/57.jpg)
§Brain malformations (Thinning/agenesis of the corpus callosum)§ Delayed myelination § Atrophy § High-signal lesions in white matter consistent with vacuolating myelin. § Abnormal glycine peak by proton MRS
Kanekar and Byler. Metab Brain Dis (2013) 28:717–720
Axial diffusion-weighted MR images in 4 day-old neonate presenting with encephalopathy and respiratory failure.(a) and (b) restricted diffusion in posterior limbs of the internal capsules (arrows). (c)Axial T2weighted image at the same level shows no signal abnormality. (d, e) Axial diffusion weighted MR images of pons show restricted diffusion in the dorsal midbrain and pons
Non-Ketotic Hyperglycinemia(GlycineEncephalopathy)
![Page 58: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/58.jpg)
Glycine
CO2
Ammonia
P H
L
T
THF
CH2-THF
FAD
FADH2
CH2-NH3
H
Fe-SNFU1
Non-Ketotic Hyperglycinemia(GlycineEncephalopathy)
Pathogenesis:NMDAReceptorOverstimulation
GlycineCleavageComplex
![Page 59: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/59.jpg)
Glycine
CO2
Ammonia
P H
L
T
THF
5,10 methyleneTHF
NAD
NADH + H+
CH2-NH3
H
GlycineCleavageComplex
Gene: GLDC
Gene : AMT
Gene : GCHS
Glycine
SLC6A9Fe-SNFU1
![Page 60: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/60.jpg)
Ø ElevatedGlycineinPlasma,Urine,CSFØ ElevatedCSF/GlycineRatioØ ElevationofCSFonlywithSLC6A9
Marker NeonatalForm AtypicalForm NormalsCSFglycineconcentration >80µmol/L >30µmol/L <20µmol/L
Plasmaglycineconcentration Varies Varies 125-450CSF/plasmaglycineratio >0.08 0.04-0.2 <0.02
ØMolecularGeneticTesting(GLDC,AMT,GCSH,NFU1,SLC6A9)ØActivityofGlycineCleavageSystem(80mglivertissue)Ø 13C-glycine Breath Test
Non-Ketotic Hyperglycinemia(GlycineEncephalopathy)Diagnosis
![Page 61: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/61.jpg)
ØBenzoate(Sodium)250-750mg/kg/dayØN-methyl-D-aspartate receptorantagonists(Ketamine,Felbamate &Dextromethorphan)
ØManagementofmanifestationsØAvoidValproate
Non-Ketotic Hyperglycinemia:Treatment
![Page 62: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/62.jpg)
Molybdenumcofactordeficiency
MbmolybdopterinSulfateoxidase xanthineoxidase
Xanthine,hypoxanthine
Uricacid
CysteineSulfites
Sulfurdioxide
Sulfate+2e-
Sulfateoxidasedeficiency Xanthineoxidasedeficiency
Genes– MOCS1,MOSC2,GPHN
Intractableseizures,infantilespasmsDysmorphicfeatures
ProgressiveencephalopathyLensdislocationEczematousrashHyperekplexia
Xanthinuria,lowuricacidArthropathy,myopathy
nephropathy,renalfailure
![Page 63: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/63.jpg)
Molybdenumcofactordeficiency
Managementandtreatment
• Antiepileptic's• Dietslowinsulfurcontainingaminoacidsalongwithsulfate
supplementationhavepositivebiochemicalresponsesbutnolastingneurologicalimprovement.
MoCo typeAdef – RX(cPMP),aprecursortoMoCo.stoppedSz,neurotoxicity– noreversal
GenetictherapywithaMOCS1 - futureRx?
![Page 64: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/64.jpg)
Impairedenergyproduction/utilization
• Mitochondrialrespiratorychain• Krebscycledisorders– PDHD,pyruvatecarboxylase
• Fattyacidoxidationdefects• Defectsingluconeogenesisorglycogenosis
![Page 65: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/65.jpg)
MitochondrialDisorders• MELAS– mitochondrialencehpalopathy,lacticacidosis,and
stroke-likeepisodes)• MERRF– myoclonicepilepsyandraggedredfibers• LHON- Leber hereditaryopticneuropathy• KSS– Kearns-Sayresyndrome• CPEO– chronicprogressiveexternalophthalmoplegia• POLG1– relateddisorders• MNGIE– mitochondrialneurogastrointestinal
encephalomyopathy• PrimarycoenzymeQ10deficiency
![Page 66: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/66.jpg)
Features• Multiplesystemsaffected
– Muscle,brain,heart,endocrine– CNSencephalopathy,Sz,dementia,stroke-likeepisodes,ataxia,spasticity,deafness,ptosis,opticatrophy,retinopathy
• Hypoglycemia,metacidosis,hypotonia,FTT• Inheritance– maternal(mito),AD,AR(nuclear)
• DX- labs,biopsies,genetictesting• RX– avoidcatabolism,vitamins,supplements
![Page 67: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/67.jpg)
POLG1– relateddisorders• NuclearencodedDNApolymerasesubunitgene• Spectrumofphenotypes• Similarwithinafamily• Multisystemic – NOTdiabetesorcardiomyopathy
– Psychiatric,Sz,extrapyramidalsymptoms,cerebellar
– Migraines,stroke-likeepisodes,SNHL,– retinopathy,ptosis,ophthalmoplegia,Cataracts,corticalvisualloss
– peripheralneuropathy,DM,ovarian/testicularfailure,liverfailure,GIdysmotility,CM
RX• AVOIDValproic acidàliverfailure• Supportivecare
– Levodopaforextrapyramidalsymptoms
• Alpers-Huttenlocher syndrome• Childhoodmyocerebrohepatic syndrome• Myoclonicepilepsymyopathysensoryataxia• Ataxianeuropathyspectrum• AR/ADprogressiveexternalophthalmoplegia
![Page 68: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/68.jpg)
MNGIE(mitochondrialneurogastrointestinal encephalomyopathy)
• Thymidinephosphorylasedeficiency– Phosphorylatesthymidine,deoxyuridine– Pyrimidinesalvage– criticalformtDNA– mtDNA deletions,mutations,depletionovertime
• Symptoms(meanonset18yo,asearlyas5mo)– SevereGIdysmotility(pseudoobstruction)– Cachexia– Ptosis/ophthalmoplegia,SNHL– Peripheralsensorimotorneuropathy(paresthesias,pain,footdrop)– Asymptomaticleukoencephalopathy
• DX– Enzymeassay(Columbia),genesequencing
![Page 69: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/69.jpg)
MNGIE(mitochondrialneurogastrointestinal encephalomyopathy)
• DX– Enzymeassay(Columbia),genesequencing
• RX– Supportive
• GI– nutritionalsupport,attentiontoswallowingdifficultiesandairwayprotection,Rxbacterialovergrowth
• Neuropathy- amitriptyline,nortriptyline,andgabapentin• PT,OT• Protectliver– TPN,carewithmedsmetabolizedbyliver• Avoidmito toxicmeds– valproate,phenytoin,Tc,metformin,trazadone
![Page 70: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/70.jpg)
Decreasedsynthesisorcatabolismofcomplexmolecules
• Lysosomal&peroxisomal disorders• Congenitaldisordersofglycosylation• Defectsincholesterolsynthesis
– SmithLemli Opitz,C-4steroldethylase
• intracellulartrafficking– NiemannPickC
![Page 71: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/71.jpg)
Features• Oftendysmorphic• Multi-systemic,progressive
– CentralandperipheralNSinvolvement,coarsefeatures,HSM
• Notriggers
• DX– labs,genetictesting• RX– limited,someenzymereplacements,BMT
![Page 72: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/72.jpg)
Alexandra Garza Flores, MD
CKPlasma amino acidsUrine organic acidsCHO def transferrin
![Page 73: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/73.jpg)
NeonatalSeizures
Etiologieshypoxic-ischemia
MeningitisHemorrhage/stroke
TraumaMalformationHypoxemia
HypocalcemiaMetabolic
Intoxication• MSUD,MMA,PA,IVA,ureacycle• Initialsymptomfreeperiod
• Sz,Poorfeeding,lethargy,respiratorydistress• HighAGmetabolicacidosis,ketosis,↑NH3
PrimaryEnergyMetabolicDefectsPyruvatemetabolism,mitochondrial
• Sz,hypotonia,poorfeed,lacticacidosis• Liverdisease,cardiomyopathy,cataracts,hearingloss,
renaltubulardefects
Peroxisomal defectsSz,hypotonia,dysmorphicfeatures,cholestasis,renalcysts,ocularabnormalities,hearingloss
C.Ficicioglu,D.Bearden/PediatricNeurology45(2011)283e291
CongenitaldisordersofGlycosylationSz,FTT,DevDelay,hepatopathy,proteinlosingenteropathy,hypoglycemia,hypotonia,immunological,skin,skeletalabnl
![Page 74: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/74.jpg)
IsolatedNeonatalSeizures• pyridoxine-dependentseizures• folinic acid-responsiveseizures• nonketotic hyperglycinemia• sulfiteoxidasedeficiency,• molybdenumcofactordeficiency• glucosetransportertype1deficiency• 4-aminobutyrateaminotransferase(g-aminobutyricacid• transferase)deficiency• congenitalneuronalceroid-lipofuscinosis• dihydropyrimidine dehydrogenasedeficiency,creatinedeficiency• syndromes,anddefectsofserinebiogenesis
NOTDETECTEDONNEWBORNSCREEN
C.Ficicioglu,D.Bearden/PediatricNeurology45(2011)283e291
![Page 75: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/75.jpg)
IsolatedNeonatalSeizures
C. Ficicioglu, D. Bearden / Pediatric Neurology 45 (2011) 283e291
![Page 76: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/76.jpg)
TreatableCausesofIsolatedNeonatalSeizures
![Page 77: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/77.jpg)
NeonatalSeizureWork-up
CBC/diff,Urinalysis,bloodglucoseElectrolytes,VBG,Ca,P,Mg,LFT,NH3BloodCSFcultures,newbornscreen,EEG
CSFanalysis– glucose(+serum)AA,L/P,CSFneurotransmitters
Urineorganicacids,plasmaaminoacidsPlasmaacylcarnitine,lactate/pyruvate,VLCFAMRI/MRS
Homocysteine,uricacidUrinepurine/pyrimidine,thiosulfateUrine/serumguandidinoacetate/creatineUrinecreatine/creatinineCarbohydratedef transferrin,N-/O-glycans?Genetictesting– infantileepilepsypanel
Forrefractory/undiagnosedSeizures
Initialevaluation
![Page 78: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/78.jpg)
CSFSTUDIES
![Page 79: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/79.jpg)
FINALREMARKS
ØHighIndexofSuspicionØ Initialmetabolicinvestigations
– Chemistries,CK,LFT’s– Ammonia– Urinalysis,urinaryreducingsubstances&ketones– Lactate,Pyruvate– PlasmaAminoAcids– PlasmaAcylcarnitine– UrinaryOrganicAcids– CSF
Ø MRI/MRS
![Page 80: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/80.jpg)
![Page 81: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/81.jpg)
References
• PKarimzadeh.ApproachtoNeurometabolic DiseasesfromaPediatricNeurologicalPointofView.IranJChildNeurol.2015Winter;9(1):1–16.
• Ibrahimetal.InbornErrorsofMetabolism:CombiningClinicalandRadiologicCluestoSolvetheMystery.AmericanJournalofRoentgenology.2014;203:W315-W327
• GFHoffmanetal.Neurologicalmanifestationsoforganicaciddisorders.Eur Jpediatr(1994)153(Suppl 1):S94-S100
• AKohlschutter.Neurologicalandneurophysiological indicesforneurometabolicdisorders.Eur Jpediatr (1994)153(Suppl 1):S90-S93
• PZoltan etal.MetabolicDisordersintheNeonate.InChapter17Part4MaryARutherfordMRIoftheNeonatalBrain.
• IHarting etal.Lookingbeyondthebasalganglia:ThespectrumofMRIchangesinmethylmalonicacidaemia. JInheritMetabDis(2008)31:368–378
• S.Kolker etal. Guidelineforthediagnosisandmanagementofglutaryl-CoAdehydrogenasedeficiency(glutaricaciduriatypeI)JInheritMetabDis(2007)30:5–22
![Page 82: Neurometabolic Disorders - Sweetser · Neurometabolic Disorders David Sweetser, MD, PhD Chief of Medical Genetics and Metabolism MassGeneral Hospital for Children Sept. 5, 2017. Disclosures](https://reader033.vdocuments.us/reader033/viewer/2022060423/5f199de6185b0809f1010ebb/html5/thumbnails/82.jpg)
• PLPearletal.Succinic semialdehyde dehydrogenasedeficiency:Lessonsfrommiceandmen. JInheritMetabDis(2009)32:343–352
• Steenweg MEetalAnoverviewofL-2-hydroxyglutaratedehydrogenasegene(L2HGDH)variants:agenotype-phenotypestudy.HumMutat.2010Apr;31(4):380-90.
• Steenweg MEetalL2-Hydroxyglutaricaciduria:patternofMRimagingabnormalitiesin56patients.Radiology.2009Jun;251(3):856-65
• SAburahma etal.Pitfallsinmeasuringcerebrospinalfluidglycinelevelsininfantswithencephalopathy.JChildNeurol.2011Jun;26(6):703-6.Epub 2011Feb18.
• SuzukiYetal.Nonketotic hyperglycinemia:Proposalofadiagnosticandtreatmentstrategy.Pediatr Neurol 2010;43:221-224.
• SKureetal.Rapiddiagnosisofglycineencephalopathyby13C-glycinebreathtest.AnnNeurol 2006;59:862-7.
• RelevantChaptersIn:Pagon RA,BirdTD,DolanCR,StephensK,editors.GeneReviews[Internet].Seattle(WA):UniversityofWashington,Seattle
• RelevantChaptersIn:CR.Scriver,WS.Sly,BChilds,AL.Beaudet,DValle,Kinzler,BVogelstein,editors.TheMetabolicandMolecularBasesofInheritedDisease
References